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Abstract
Background: Insulin resistance is accompanied by a cluster of metabolic changes, often referred to as metabolic
syndrome. Metabolic syndrome is associated with an increased cardiovascular risk in patients with manifest arterial
disease. We investigated whether insulin resistance is associated with an increased risk for cardiovascular events in
patients with manifest arterial disease without known diabetes and whether this can be explained by the
components of the metabolic syndrome or by inflammation.
Methods: Prospective cohort study in 2611 patients with manifest arterial disease without known diabetes.
Homeostasis model of insulin resistance (HOMA-IR) was used to quantify insulin resistance. The relation of HOMA-IR
with cardiovascular events (vascular death, myocardial infarction or stroke) and all cause mortality was assessed
with Cox regression analysis. In additional models adjustments were performed for the single components
constituting the metabolic syndrome and for inflammation.
Results: HOMA-IR increases with the number of metabolic syndrome components (mean HOMA-IR ± SD in groups
with 0, 1, 2, 3, 4 and 5 metabolic syndrome components: 1.4 ± 0.7; 1.8 ± 1.2; 2.4 ± 1.5; 3.1 ± 1.8; 4.0 ± 2.6; and 5.6
± 3.6 respectively). High HOMA-IR was independently associated with an increased risk of cardiovascular events
(tertile 2 vs. 1 HR 1.92; 95%CI 1.20-3.08) (tertile 3 vs.1 HR 1.78; 95%CI 1.10-2.89) and with all cause mortality (tertile 2
vs. 1 HR 1.80; 95%CI 1.04-3.10) (tertile 3 vs.1 HR 1.56; 95%CI 0.88-2.75). These relations were not influenced by the
individual components of metabolic syndrome or by inflammation.
Conclusions: In patients with manifest arterial disease without known diabetes, insulin resistance increases with
the number of metabolic syndrome components, and elevated insulin resistance increases the risk of new
cardiovascular events.
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Background
Both insulin resistance and metabolic syndrome are
recognized as important factors in the development of
cardiovascular disease [1,2]. Obesity-induced insulin
resistance is considered to be the major driver of the
clustering of interrelated metabolic disturbances (e.g.
dyslipidemia, hyperglycemia, elevated blood pressure)[3],
often referred to as metabolic syndrome [4], thereby
leading to an increased cardiovascular risk. Although
insulin resistance may be the unifying pathophysiological
mechanism underlying the metabolic syndrome [5],
there is uncertainty regarding the independent role of
insulin resistance in the development of atherosclerotic
vascular disease [1,5-12], also in patients with arterial
diseases [13,14].
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with manifest arterial disease (46%)[15] and is associated
with advanced vascular damage [16], thereby identifying
those patients with an even higher cardiovascular risk.
This high cardiovascular risk may be due to a combina-
tion of non-classical risk factors associated with insulin
resistance, e.g. inflammation, hyperinsulinemia, oxidative
stress, and hypercoagulability, together with the separate
components of metabolic syndrome (low high-density
lipoprotein (HDL)-cholesterol, elevated triglycerides, ele-
vated glucose, elevated blood pressure, increased waist
circumference)[17-19]. Nevertheless, the magnitude of
the association between insulin resistance and the
occurrence of new vascular events in these high-risk
patients is not yet elucidated. In addition, it is not
known whether insulin resistance per se has an influence
on the elevated cardiovascular risk or that it is mediated
by the components of metabolic syndrome.
Aim of the current study is (1) to investigate the rela-
tion between insulin resistance and metabolic distur-
bances, (2) to determine whether insulin resistance,
derived by homeostasis model assessment of insulin
resistance (HOMA-IR), is associated with increased
occurrence of cardiovascular events and all cause mor-
tality, and (3) to evaluate to what extent this relation
can be explained by the individual components of the
metabolic syndrome or by inflammation.
Methods
Study settings, participants and design
In this study, we used data from patients enrolled in the
Second Manifestations of Arterial disease (SMART)
study. The SMART study is an ongoing prospective sin-
gle-centre cohort study in patients with manifest arterial
disease or cardiovascular risk factors [20]. Started in
September 1996, patients aged 18-80, were referred to
the University Medical Centre (UMC) Utrecht with a
recent diagnosis of manifest arterial disease or a cardio-
vascular risk factor. Not approached are patients with
terminal malignant disease, those not independent in
daily activities (Rankin scale > 3) or not sufficiently flu-
ent in Dutch. Patients entered the SMART study if par-
ticipation in the study was supported by the treating
specialist and if the patients themselves consented to
participate. The Medical Ethics Committee approved the
study, and all participants gave their written informed
consent. The rationale and design of the SMART study
and a detailed description of the criteria used to define
the different manifest arterial diseases were published
previously [20].
For the current study, the data of the 3239 participants
with clinical manifestations of arterial disease (coronary
heart disease, cerebrovascular disease, peripheral arterial
disease or abdominal aortic aneurysm) included between
July 1, 2003 and March 1, 2010 were considered. A total
of 548 patients with known Type 1 or Type 2 diabetes
mellitus (T2DM) were not included in the analyses. Dia-
betes mellitus at baseline was defined as a referral diag-
nosis of diabetes, self-reported diabetes, or use of glucose
lowering agents. If glucose was ≥ 7 mmol/l without a his-
tory of diabetes, patients were only included if they were
not on glucose lowering therapy after 1 year follow up
[21]. In addition, patients with missing data on glucose
or insulin were excluded (n = 44).
Data acquisition
All baseline measurements were performed on a single
day at the UMC Utrecht. Medical history, use of current
medication and current and past cigarette smoking
behavior were derived from a questionnaire described
elsewhere [20]. Height, weight, waist circumference and
blood pressure were measured. Blood samples were col-
lected after an overnight fast. Total cholesterol, trigly-
cerides, HDL-cholesterol, creatinin, and high sensitive-
C-reactive protein (hs-CRP) levels were measured. Hs-
CRP measurements below the lower limit of detection
of 0.2 mg/l (n = 45) were set at 0.2 mg/l. Plasma glucose
was measured using commercial enzymatic dry chemis-
try kits (Johnson and Johnson). Plasma insulin was mea-
sured with an immunometric technique on an
IMMULITE 1000 Analyzer (Diagnostic Products Cor-
poration, Los Angeles, USA). Inter-assay coefficient of
variation for insulin measurements was 9% at 7 mIU/l
and < 5.5% at 20-120 mIU/l. Insulin measurements
below the lower limit of detection of 2 mIU/l (n = 74)
were set at 2 mIU/l.
HOMA-IR was used as quantitative estimate of the
degree of insulin resistance at baseline. The value for
insulin resistance can be assessed by the formula:
HOMA-IR = (fasting serum glucose (mmol/l) × fasting
serum insulin (mIU/l)/22.5)[22]. HOMA-IR correlates
well with measurements obtained by means of the
euglycemic clamp technique [23]. Therefore it provides
a reliable approach to estimate insulin resistance and
lends itself for use in large epidemiological studies [24].
In addition, quantitative insulin sensitivity check index
(QUICKI) was measured to compare the results
retrieved with HOMA. QUICKI was calculated with the
formula QUICKI = 1/(log(insulin × glucose))[25].
Metabolic syndrome was defined according to the
Adult Treatment Panel (ATP) III criteria [4]. Metabolic
syndrome requires the presen c eo fa tl e a s tt h r e eo ft h e
following metabolic abnormalities: abdominal obesity
(waist circumference > 102 cm in men and > 88 cm in
women), high blood pressure (≥ 130 mmHg systolic or
≥ 85 mmHg diastolic), hypertriglyceridemia (serum tri-
glycerides ≥ 1.70 mmol/l (150 mg/dl)), low HDL-choles-
terol (serum HDL-cholesterol < 1.04 mmol/l (40 mg/dl)
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fasting glucose (fasting serum glucose ≥ 5.6 mmol/l (100
mg/dl)). Patients on blood pressure-lowering medication
were regarded as having high blood pressure.
Follow up
All patients were asked to complete a questionnaire
every 6 months. The questionnaire comprised of ques-
tions on hospital admissions and out-patient clinic vis-
its in the preceding 6 months. If patients reported a
possible event, hospital discharge letters and results of
relevant laboratory results and radiology examinations
were collected and evaluated by an Outcome Event
Committee comprising of physicians from different
departments. Outcome of interest for the present study
was a composite endpoint of fatal or non-fatal cardio-
vascular events during follow-up. A cardiovascular
event was defined as the occurrence of cardiovascular
death, ischemic stroke or myocardial infarction (table
1 ) .F o r t y - t w oo u to f2 6 1 1p a t i e n t s( 2 % )w e r el o s tt o
follow-up. Duration of follow-up was defined as the
period between the date of study inclusion and the
date of the occurrence of a new cardiovascular event,
date of loss to follow-up or the pre-selected closing
date of March 1
st, 2010.
Data analysis
Baseline characteristics were reported across tertiles of
HOMA-IR. Mean and standard deviation (SD) were
reported if continuous variables were normally distribu-
ted and median and interquartile range if distributions
were skewed. Differences between tertiles of HOMA-IR
were tested with one-way ANOVA (continuous normal
distributed variables) or Kruskal-Wallis test (continuous
skewed variables).
A trend between the number of components of meta-
bolic syndrome and HOMA-IR was investigated with
ANCOVA (general linear model procedure), and
adjusted for age and gender.
The hazard ratios (HR) with corresponding 95% confi-
dence intervals (CI) for the occurrence of a new cardio-
vascular event and of total mortality associated with
insulin resistance were estimated with Cox proportional
hazards analysis. Three models were used to estimate
the relation between HOMA-IR as independent variable
and new cardiovascular events or total mortality as
dependent variables. Model 1 was adjusted for age and
gender. In model 2 additional adjustments were made
for current smoking, use of lipid lowering medication
and blood pressure lowering medication. In model 3
exploratory analyses are shown with additional adjust-
ments for history of coronary artery disease, cerebrovas-
cular disease, abdominal aortic aneurysm and peripheral
arterial disease on top of model 2. Analyses were
repeated with QUICKI as independent variable.
To investigate whether the relation between insulin
resistance and cardiovascular disease can be explained
by the single components of the metabolic syndrome or
by inflammation, additional adjustments for waist cir-
cumference, HDL-cholesterol, triglycerides, fasting glu-
cose, systolic blood pressure and hs-CRP were
performed on top of model 2 (model 4). Significance
was taken at the 5% level (two-sided).
To investigate whether the relation between HOMA-
IR and new cardiovascular events is modified by other
variables, interaction terms for age, gender, waist cir-
cumference and smoking were subsequently included in
model 2. The p-values of these interaction terms were >
0.05 and it was concluded that no effect modification
was present for these variables.
In the Cox regression analyses, single imputation meth-
ods were used to reduce missing covariate data for smoking
(n = 3 (< 1%)), HDL-cholesterol (n = 4 (< 1%)), triglycerides
(n = 2 (< 1%)), systolic blood pressure (n = 13 (< 1%)),
Table 1 Definition of study outcome events
Stroke Definite: relevant clinical features causing an increase in impairment of at least one grade on the modified Rankin
scale, accompanied by an infarction on repeat brain imaging.
Probable: clinical features that have caused an increase in impairment of at least one grade on the modified Rankin
scale; without documentation by means of brain imaging.
Myocardial infarction At least two of the following criteria:
(I) chest pain for at least 20 min, not disappearing after administration of nitrates;
(II) ST-elevation > 1 mm in two following leads or a left bundle branch block on the electrocardiogram;
(III) Creatinine kinase (CK) elevation of at least two times the normal value of CK and a myocardial band-fraction > 5%
of the total CK.
Vascular mortality Death from ischemic or hemorrhagic stroke, congestive heart failure, myocardial infarction or rupture of abdominal
aortic aneurysm.
Sudden death: unexpected cardiac death occurring within 1 hour after onset of symptoms, or within 24 hours given
convincing circumstantial evidence.
Vascular death from other causes
Composite vascular
outcome event
A composite of stroke, myocardial infarction and vascular mortality completed with a probable or definite retinal
infarction or bleeding and probable or definite hemorrhagic stroke.
All-cause mortality Death from any cause
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since incomplete case analysis leads to loss of statistical
power and possibly bias.
Results
Study population
The mean age was 59.6 ± 10.4 years and 71% of patients
were male. HOMA-IR levels were 2.9 ± 2.2 for males
and 2.5 ± 1.8 for females. CIMT and incidence of albu-
minuria did not change substantially across tertiles of
HOMA-IR. Further general characteristics of the study
population according to tertiles of HOMA-IR are listed
in table 2.
Insulin resistance and metabolic disturbances
Prevalence of metabolic syndrome was 42%. Metabolic
syndrome was more prevalent in the highest HOMA-IR
tertile compared with the lowest tertile (69% versus
16%) (table 2). Waist circumference, fasting glucose
level, triglyceride level and systolic blood pressure were
higher in patients within the highest HOMA-IR tertile,
whereas HDL-cholesterol level was lower. Level of hs-
CRP was incurred with increasing levels of insulin resis-
tance. It is shown that HOMA-IR increases with an
increment in the number of components of metabolic
syndrome, adjusted for age and gender (p-value for
trend < 0.001). (table 3)
Insulin resistance and occurrence of cardiovascular events
During a mean follow-up of 3.1 ± 1.9 years (total number
of follow-up years 8094), 91 out of 2611 subjects died (of
whom 47 due to a cardiovascular cause), 74 experienced a
myocardial infarction and 34 an ischemic stroke. This cor-
responds with a cardiovascular event rate of 16 per 1000
Table 2 Baseline characteristics of the study population (n = 2611) according to tertiles of HOMA-IR
HOMA-IR, tertiles Tertile 1 Tertile 2 Tertile 3
HOMA-IR 1.1 ± 0.4 2.3 ± 0.4 4.9 ± 2.3
(Range) 0.4-1.7 1.7-3.0 3.0-23.3
n = 872 n = 870 n = 869
Age (years) 59.4 ± 10.5 60.0 ± 10.4 59.4 ± 10.4
Male gender, n (%) 593 (68) 611 (70) 658 (76)
Body mass index (kg/m
2) 24.7 ± 3.1 26.7 ± 3.4 28.9 ± 4.2
Abdominal adipose tissue (cm) 7.6 ± 2.0 8.7 ± 2.2 10.1 ± 2.5
Current smoking, n (%) 288 (33) 245 (28) 251 (29)
Creatinin clearance MDRD (ml/min/1.73 m2) 79.0 ± 16.8 75.4 ± 16.4 74.0 ± 18.3
Medication
Lipid-lowering agents, n (%) 624 (72) 671 (77) 709 (82)
Anti-platelet agents, n (%) 689 (79) 723 (83) 724 (83)
Blood pressure-lowering agents, n (%) 588 (67) 654 (75) 751 (86)
Location of manifest arterial disease
Cerebrovascular disease, n (%) 263 (30) 261 (30) 206 (24)
Coronary heart disease, n (%) 509 (58) 540 (62) 614 (71)
Peripheral arterial disease, n (%) 138 (16) 127 (15) 133 (16)
Abdominal aortic aneurysm, n (%) 56 (6) 64 (7) 44 (5)
Atherosclerotic burden
CIMT(mm) 0.88 ± 0.24 0.89 ± 0.25 0.89 ± 0.22
Albumin/creatinin ratio > 3.0 mg/mmol, n (%) 120 (14) 120 (14) 135 (16)
Metabolic syndrome components
Metabolic syndrome (ATPIII), n (%) 148 (17) 232 (37) 582 (67)
Waist circumference (cm) 87.6 ± 10.6 94.0 ± 10.5 100.5 ± 11.8
Blood pressure systolic (mmHg) 138 ± 20 141 ± 21 142 ± 21
Blood pressure diastolic (mmHg) 81 ± 11 83 ± 11 84 ± 11
Fasting glucose (mmol/l) 5.4 ± 0.5 5.7 ± 0.6 6.1 ± 0.8
Triglycerides (mmol/l) 1.0 (0.8-1.4) 1.2 (0.9-1.7) 1.1 (0.9-1.3)
HDL-cholesterol (mmol/l) 1.4 ± 0.4 1.3 ± 0.4 1.1 ± 0.3
LDL-cholesterol (mmol/l) 2.7 ± 0.9 2.7 ± 1.0 2.6 ± 0.9
hs-CRP (mg/l) 1.4 (0.6-3.2) 1.6 (0.8-3.7) 2.1 (1.0-4.3)
Fasting insulin (mIU/l) 4.8 ± 1.6 9.1 ± 1.5 17.9 ± 7.8
QUICKI 0.32 ± 0.05 0.26 ± 0.01 0.22 ± 0.02
Verhagen et al. Cardiovascular Diabetology 2011, 10:100
http://www.cardiab.com/content/10/1/100
Page 4 of 9patient years and a mortality rate of 11 per 1000 patient
years. HOMA-IR was associated with an increased risk for
the occurrence of a new vascular event, adjusted for age,
gender, smoking and use of lipid lowering and blood pres-
sure lowering medication (tertile 2 versus 1 HR 1.92 (95%
confidence interval (CI) 1.20-3.08); (tertile 3 versus 1
HR1.78 (95%CI 1.10-2.89) (table 4)). Comparison of the
lower tertiles of QUICKI with the highest tertile yielded
exactly the same HRs as comparison of the higher
HOMA-IR tertiles with the first tertile (table 5). Risk of
death from any cause was increased in the second tertile
of HOMA-IR versus the first (HR 1.80, (95%CI 1.05-3.10)
and this risk was also increased, although non-statistically
significant, in the third versus the first tertile (HR 1.56
(95%CI: 0.88-2.75).
Influence of metabolic syndrome and inflammation on
the relation between insulin resistance and cardiovascular
risk
To investigate the independent relation between insulin
resistance and cardiovascular events, additional analyses
were performed adjusting for factors that are possibly in
the causal pathway. Adjusting for the individual compo-
nents of the metabolic syndrome did not substantially
change the relation between HOMA-IR and the composite
endpoint of all vascular events (tertile 2 versus 1 HR 1.76;
95%CI 1.08-2.89; tertile 3 versus 1 HR 1.48; 95%CI 0.83-
2.63). Congruently adjustment for presence of the meta-
b o l i cs y n d r o m ed i dn o ta l t e rt h ep o i n te s t i m a t ef o rt h e
relation between HOMA-IR and the composite endpoint
(tertile 2 vs 1 HR 1.92 95%CI 1.20-3.08; tertile 3 vs1 (HR
Table 3 HOMA-IR in relation to metabolic syndrome (ATPIII) and the number of metabolic syndrome components in
patients with manifest arterial disease
n = 2611 N HOMA-IR QUICKI p-value
Metabolic syndrome no 1478 2.1 ± 1.4 0.28 ± 0.05 < 0.001
yes 1053 3.7 ± 2.5 0.24 ± 0.04
Metabolic syndrome components 0 137 1.4 ± 0.7 0.31 ± 0.05 < 0.001
1 547 1.8 ± 1.2 0.30 ± 0.06
2 794 2.4 ± 1.5 0.27 ± 0.05
3 573 3.1 ± 1.8 0.25 ± 0.04
4 366 4.0 ± 2.6 0.23 ± 0.03
5 114 5.6 ± 3.6 0.22 ± 0.03
Table 4 HOMA-IR and the risk for new cardiovascular events (vascular death, myocardial infarction or stroke) in
patients with manifest arterial disease (n = 2611)
HOMA-IR tertile 1 tertile 2 tertile 3
Model # events HR (95%CI) # events HR (95%CI) # events HR (95%CI)
All vascular events 1 26 1 (reference) 52 1.86 (1.16-2.98) 48 1.70 (1.05-2.74)
2 1 (reference) 1.92 (1.20-3.08) 1.78 (1.10-2.89)
3 1 (reference) 1.86 (1.16-3.00) 1.79 (1.10-2.90)
4 1 (reference) 1.80 (1.10-2.96) 1.50 (0.85-2.68)
Myocardial infarction 1 17 1 (reference) 30 1.63 (0.90-2.96) 27 1.42 (0.77-2.61)
2 1 (reference) 1.61 (0.89-2.93) 1.41 (0.76-2.61)
3 1 (reference) 1.57 (0.86-2.85) 1.39 (0.75-2.59)
4 1 (reference) 1.34 (0.72-2.51) 0.95 (0.46-1.98)
All cause mortality 1 20 1 (reference) 39 1.69 (0.99-2.91) 32 1.43 (0.82-2.51)
2 1 (reference) 1.80 (1.05-3.10) 1.56 (0.88-2.75)
3 1 (reference) 1.76 (1.02-3.03) 1.63 (0.92-2.88)
4 1 (reference) 1.83 (1.04-3.24) 1.56 (0.78-3.09)
Vascular mortality 1 9 1 (reference) 23 2.26 (1.04-4.88) 15 1.50 (0.66-3.43)
2 1 (reference) 2.42 (1.12-5.25) 1.72 (0.74-3.98)
3 1 (reference) 2.24 (1.03-4.88) 1.74 (0.75-4.04)
4 1 (reference) 2.56 (1.15-5.70) 1.85 (0.73-4.73)
Model 1: adjusted for age and gender
Model 2: model I additionally adjusted for current smoking, lipid lowering medication, blood pressure-lowering medication
Model 3: model II additionally adjusted for history of coronary artery disease, cerebrovascular disease, abdominal aortic aneurysm and peripheral arterial disease.
Model 4: model II additionally adjusted for waist circumference, systolic blood pressure, triglycerides, HDL-c, glucose and hs-CRP
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altered after adjusting for hs-CRP as a marker of inflam-
mation (tertile 2 versus 1 HR 1.93; 95%CI 1.20-3.10; tertile
3 versus 1 HR 1.73; 95%CI 1.07-2.82). Hazard ratios for
analyses with the single components of the metabolic syn-
drome and hs-CRP are depicted in table 4, model 4.
Discussion
In patients with manifest arterial diseases without
known diabetes, insulin resistance was elevated in
patients with a higher number of metabolic syndrome
components pointing towards a causal role of insulin
resistance in the pathophysiology of metabolic syn-
drome. Furthermore, in this population, insulin resis-
tance is associated with an increased risk to develop a
second vascular event, independent of risk factors clus-
tering in the metabolic syndrome including inflamma-
tion. Insulin resistance also tended to be associated with
an increased risk of death form any cause, although the
relationship between insulin resistance and all-cause
mortality was not statistically significant in the highest
tertile of HOMA-IR
These results imply that insulin resistance is a major
driver underlying the clustering of metabolic abnormal-
ities and that insulin resistance is also directly and inde-
pendently related to an increased risk for cardiovascular
events in patients with manifest arterial disease. In gen-
eral, patients with insulin resistance are at increased car-
diovascular risk [1,5-12]. Two other studies have shown
that insulin resistance is associated with an increased
risk for new vascular events in patients with manifest
arterial disease [13,14]. Furthermore HOMA-IR has
been found to independently predict the occurrence of a
secondary event in patients with acute coronary syn-
drome [26]. In these studies, HOMA-IR was lower and
the range was less broad as compared to the present
study. The reason for the relatively high HOMA-IR in
our cohort is not fully clear and not attributable to high
BMI, since BMI in our study population was comparable
or even lower than in these previous studies.
Obesity is associated with the metabolic abnormalities
and an increased blood pressure clustered in the meta-
bolic syndrome [3]. With an increase in adipocyte size,
capillary density in adipose tissue decreases by an
increase in collagen IV in the capillary walls, preventing
angiogenesis in vitro [27]. Oxidative stress caused by a
decreased capillary density may be the underlying
mechanism of adipose tissue dysfunction characterized
by secretion of pro-inflammatory cytokines and meta-
bolic changes [28]. As a result of adipose tissue dysfunc-
tion efflux of free fatty acids increases, eventually giving
rise to systemic dyslipidemia [29] One of the potential
mechanisms for obesity-associated hypertension linking
hypertension and insulin resistance is a decrease in car-
diac natriuretic peptides as observed in insulin resis-
tance [30].
Results of the present study are clinically relevant,
since improving insulin sensitivity may improve
Table 5 QUICKI and the risk for new cardiovascular events (vascular death, myocardial infarction or stroke) in patients
with manifest arterial disease (n = 2611)
QUICKI tertile 1 tertile 2 tertile 3
Model # events HR (95%CI) # events HR (95%CI) # events HR (95%CI)
All vascular events 1 48 1.70 (1.05-2.74) 52 1.86 (1.16-2.98) 26 1 (reference)
2 1.78 (1.10-2.89) 1.92 (1.20-3.08) 1 (reference)
3 1.79 (1.10-2.90) 1.86 (1.16-3.00) 1 (reference)
4 1.50 (0.85-2.68) 1.80 (1.10-2.96) 1 (reference)
Myocardial infarction 1 27 1.42 (0.77-2.61) 30 1.63 (0.90-2.96) 17 1 (reference)
2 1.41 (0.76-2.61) 1.61 (0.89-2.93) 1 (reference)
3 1.39 (0.75-2.59) 1.57 (0.86-2.85) 1 (reference)
4 0.95 (0.46-1.98) 1.34 (0.72-2.51) 1 (reference)
All cause mortality 1 32 1.43 (0.82-2.51) 39 1.69 (0.99-2.91) 20 1 (reference)
2 1.56 (0.88-2.75) 1.80 (1.05-3.10) 1 (reference)
3 1.63 (0.92-2.88) 1.76 (1.02-3.03) 1 (reference)
4 1.56 (0.78-3.09) 1.83 (1.04-3.24) 1 (reference)
Vascular mortality 1 15 1.50 (0.66-3.43) 23 2.26 (1.04-4.88) 9 1 (reference)
2 1.72 (0.74-3.98) 2.42 (1.12-5.25) 1 (reference)
3 1.74 (0.75-4.04) 2.24 (1.03-4.88) 1 (reference)
4 1.85 (0.73-4.73) 2.56 (1.15-5.70) 1 (reference)
Model 1: adjusted for age and gender
Model 2: model I additionally adjusted for current smoking, lipid lowering medication, blood pressure-lowering medication
Model 3: model II additionally adjusted for history of coronary artery disease, cerebrovascular disease, abdominal aortic aneurysm and peripheral arterial disease.
Model 4: model II additionally adjusted for waist circumference, systolic blood pressure, triglycerides, HDL-c, glucose and hs-CRP
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patients with type 2 diabetes [31,32]. In a randomized
trial investigating the optimal treatment in diabetic
patients with stable ischemic heart disease, there was a
trend towards a lower cardiovascular risk for insulin
sensitization compared to insulin provision in the group
of patients randomized to undergo revascularization as
opposed to medical therapy alone [32]. Improving insu-
lin sensitivity with the peroxisome proliferator-activated
receptor (PPAR-)g agonist pioglitazone was demon-
strated to reduce the occurrence of macrovascular
events in patients with type 2 diabetes [31].
The increased occurrence of cardiovascular events in
patients with insulin resistance is most likely due to
atherosclerotic disease. Arterial stiffness is considered to
be an early manifestation of atherosclerosis. In non-dia-
betic subjects, fasting glucose was associated with arterial
stiffness as measured with pulse wave velocity [33]. In
patients without diabetes, pulse wave velocity was an
independent predictor for intima media thickness, but
not in patients with diabetes [34]. The mechanisms by
which insulin resistance leads to atherosclerotic cardio-
vascular disease are not fully understood. Indirect effects
through accelerating chronic inflammation, oxidative
stress, and metabolic abnormalities (e.g. hyperglycemia,
dyslipidemia, and elevated blood pressure) have been
implicated to contribute to endothelial dysfunction,
thereby enhancing atherosclerotic cardiovascular disease
[17,35]. In patients with manifest arterial disease the sin-
gle components of the metabolic syndrome did not
increase the risk of new vascular events in contrast to
these components combined in the metabolic syndrome
[36]. The metabolic syndrome is under debate because of
its limited additive value in prediction of cardiovascular
disease on top of classical risk factors [37]. However,
from an etiologic point of view, the concept of the meta-
bolic syndrome helps us to understand the pathophysiol-
ogy of insulin resistance and its related metabolic
changes leading to an increased cardiovascular risk. In
the present study we have evaluated the etiologic relation
between insulin resistance and cardiovascular risk. Meta-
bolic syndrome is highly related to insulin resistance.
In our analyses, adjusting for the individual compo-
nents of the metabolic syndrome did not alter the rela-
tion between insulin resistance and the risk of new
vascular events. This implies that, besides the compo-
nents constituting the metabolic syndrome, there are
other factors that drive the relationship between insulin
resistance and the risk of new cardiovascular endpoints.
In adipose tissue dysfunction adipocytes enlarge giving
rise to insulin resistance and an increase in adipocytokine
production leading to a pro-inflammatory state. How-
ever, our analyses do not point to inflammation as a key
factor in the relationship between insulin resistance and
vascular disease as adjustment for hs-CRP did not sub-
stantially influence the point estimate for the risk of car-
diovascular events across tertiles of HOMA-IR. Besides
pro-inflammatory effects, adipocytokines are known to
induce pro-haemostatic, pro-coagulant effects [38],
although platelet aggregation is reduced in hyperinsuline-
mic states [39]. Furthermore endothelial function is
impaired in insulin resistance through imbalance of nitric
oxide production and the release of vasoconstrictor
endothelin-1[40]. Various adipocytokines may also
directly affect endothelial function and accelerate pro-
cesses involved in atherogenesis. Another explanation
m a yb et h ec h a n g ei nl i p o p r o t ein particle composition.
Insulin resistance is associated with the pro-atherogenic
small dense LDL-cholesterol concentration [41].
We acknowledge some limitations of our study. Com-
pared to other studies with comparable patient groups,
there was a relatively low mortality rate, limiting the sta-
tistical power of the study. HOMA-IR was used to esti-
mate the level of insulin resistance. Although the
hyperinsulinemic euglycemic clamp technique is the
standard for measuring insulin resistance [42], this tech-
nique is unsuitable for epidemiologic studies. HOMA-IR
seems to be a reliable tool in the assessment of insulin
resistance due to its strong relation to clamp-measured
insulin resistance in both patients with and without dia-
betes [23,24]. Moreover, repeating analyses with the
QUICKI index as a measure of insulin sensitivity con-
firmed the results retrieved with HOMA-IR. It can be
agued that it is not correct to include glucose in models
together with HOMA-IR. However since hyperglycemia
is one of the effects of insulin resistance and part of the
metabolic syndrome just as dyslipidemia and hyperten-
sion, we decided to adjust for all components of the
metabolic syndrome including glucose. Moreover, there
is no single clinical definition for the clustering of meta-
bolic abnormalities. We used the ATPIII-definition of
metabolic syndrome [4] because it is most commonly
used in studies, best related with the development of
vascular diseases and easy to use in clinical practice.
However, we realize that there are more definitions for
the metabolic syndrome [3].
In conclusion, in patients with manifest arterial disease
without diabetes, insulin resistance clusters with the
number of components of the metabolic syndrome, and
elevated insulin resistance is independently associated
with an increased risk for cardiovascular events. This
relation can not be explained by the single components
constituting the metabolic syndrome or by inflammation.
Acknowledgements
The SMART study was financially supported by a grant of the UMC Utrecht,
The Netherlands. The help of R. van Petersen for data coordination is greatly
acknowledged.
Verhagen et al. Cardiovascular Diabetology 2011, 10:100
http://www.cardiab.com/content/10/1/100
Page 7 of 9SMART Study Group: A. Algra, Julius Centre for Health Sciences and Primary
Care and Rudolph Magnus Institute of Neuroscience, Department of
Neurology; Y. van der Graaf, G.E.H.M. Rutten, D.E. Grobbee, Julius Centre for
Health Sciences and Primary Care; F.L.J. Visseren, Department of Vascular
Medicine; P.A. Doevendans, Department of Cardiology; F.L. Moll, Department
of Vascular Surgery; L.J. Kappelle, Department of Neurology; W.P.Th.M. Mali,
Department of Radiology.
Author details
1Department of Vascular Medicine, University Medical Centre Utrecht (UMC
Utrecht), Utrecht, The Netherlands.
2Julius Centre for Health Sciences and
Primary Care, UMC Utrecht, Utrecht, The Netherlands.
Authors’ contributions
All authors have read and approved the final manuscript. SV carried out the
analyses, had an important part in the conception of the present study,
interpretation of the data and in writing the manuscript. YG participated in
the design of the SMART-study and critically reviewed the analyses and the
design of the present study. AW participated in performing the analyses and
critically reviewed the manuscript. PG participated in the conception of the
present study and made a substantial contribution in drafting the
manuscript. FV made substantial contributions in interpretation of the data,
conception of the present study and in writing the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 October 2011 Accepted: 21 November 2011
Published: 21 November 2011
References
1. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB,
Bonadonna RC, Muggeo M: Insulin resistance as estimated by
homeostasis model assessment predicts incident symptomatic
cardiovascular disease in caucasian subjects from the general
population: the Bruneck study. Diabetes Care 2007, 30:318-324.
2. Lakka HM, Lakka TA, Tuomilehto J, Salonen JT: Abdominal obesity is
associated with increased risk of acute coronary events in men. Eur
Heart J 2002, 23:706-713.
3. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005,
365:1415-1428.
4. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA,
Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F:
Diagnosis and management of the metabolic syndrome: an American
Heart Association/National Heart, Lung, and Blood Institute Scientific
Statement. Circulation 2005, 112:2735-2752.
5. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L,
Saggiani F, Poli M, Perbellini S, Raffaelli A, Cacciatori V, Santi L, Targher G,
Bonadonna R, Muggeo M: HOMA-estimated insulin resistance is an
independent predictor of cardiovascular disease in type 2 diabetic
subjects: prospective data from the Verona Diabetes Complications
Study. Diabetes Care 2002, 25:1135-1141.
6. Adler AI, Levy JC, Matthews DR, Stratton IM, Hines G, Holman RR: Insulin
sensitivity at diagnosis of Type 2 diabetes is not associated with
subsequent cardiovascular disease (UKPDS 67). Diabet Med 2005,
22:306-311.
7. Hanley AJ, Williams K, Stern MP, Haffner SM: Homeostasis model
assessment of insulin resistance in relation to the incidence of
cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002,
25:1177-1184.
8. Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L: Insulin resistance
in non-diabetic subjects is associated with increased incidence of
myocardial infarction and death. Diabet Med 2002, 19:470-475.
9. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D’Agostino RB Sr, Wilson PW:
Impact of insulin resistance on risk of type 2 diabetes and
cardiovascular disease in people with metabolic syndrome. Diabetes Care
2007, 30:1219-1225.
10. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV:
Insulin resistance, the metabolic syndrome, and risk of incident
cardiovascular disease in nondiabetic american indians: the Strong Heart
Study. Diabetes Care 2003, 26:861-867.
11. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW: Insulin
resistance, the metabolic syndrome, and incident cardiovascular events
in the Framingham Offspring Study. Diabetes 2005, 54:3252-3257.
12. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H: The metabolic
syndrome, insulin resistance, and cardiovascular risk in diabetic and
nondiabetic patients. J Clin Endocrinol Metab 2005, 90:5698-5703.
13. Tenenbaum A, Adler Y, Boyko V, Tenenbaum H, Fisman EZ, Tanne D,
Lapidot M, Schwammenthal E, Feinberg MS, Matas Z, Morto M, Behar S:
Insulin resistance is associated with increased risk of major
cardiovascular events in patients with preexisting coronary artery
disease. Am Heart J 2007, 153:559-565.
14. Yanase M, Takatsu F, Tagawa T, Kato T, Arai K, Koyasu M, Horibe H,
Nomoto S, Takemoto K, Shimizu S, Watarai M: Insulin resistance and
fasting hyperinsulinemia are risk factors for new cardiovascular events
in patients with prior coronary artery disease and normal glucose
tolerance. Circ J 2004, 68:47-52.
15. Gorter PM, Olijhoek JK, van der Graaf Y, Algra A, Rabelink TJ, Visseren FL:
Prevalence of the metabolic syndrome in patients with coronary heart
disease, cerebrovascular disease, peripheral arterial disease or
abdominal aortic aneurysm. Atherosclerosis 2004, 173:363-369.
16. Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL: The
metabolic syndrome is associated with advanced vascular damage in
patients with coronary heart disease, stroke, peripheral arterial disease
or abdominal aortic aneurysm. Eur Heart J 2004, 25:342-348.
17. Martens FM, Visseren FL: The operative risk factors in the metabolic
syndrome: is it lipids and high BP or are there direct vascular effects of
insulin resistance and obesity. Curr Diab Rep 2007, 7:74-81.
18. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP: Clustering of
procoagulation, inflammation, and fibrinolysis variables with metabolic
factors in insulin resistance syndrome. Am J Epidemiol 2000, 152:897-907.
19. Scuteri A, Najjar SS, Muller DC, Andres R, Hougaku H, Metter EJ, Lakatta EG:
Metabolic syndrome amplifies the age-associated increases in vascular
thickness and stiffness. J Am Coll Cardiol 2004, 43:1388-1395.
20. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y: Second
manifestations of ARTerial disease (SMART) study: rationale and design.
Eur J Epidemiol 1999, 15:773-781.
21. Wassink AM, van der Graaf Y, van Haeften TW, Spiering W, Soedamah-
Muthu SS, Visseren FL: Waist circumference and metabolic risk factors
have separate and additive effects on the risk of future Type 2 diabetes
in patients with vascular diseases. A cohort study. Diabet Med 2011,
28:932-940.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC:
Homeostasis model assessment: insulin resistance and beta-cell function
from fasting plasma glucose and insulin concentrations in man.
Diabetologia 1985, 28:412-419.
23. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB,
Monauni T, Muggeo M: Homeostasis model assessment closely mirrors
the glucose clamp technique in the assessment of insulin sensitivity:
studies in subjects with various degrees of glucose tolerance and insulin
sensitivity. Diabetes Care 2000, 23:57-63.
24. Haffner SM, Miettinen H, Stern MP: The homeostasis model in the San
Antonio Heart Study. Diabetes Care 1997, 20:1087-1092.
25. Muniyappa R, Lee S, Chen H, Quon MJ: Current approaches for assessing
insulin sensitivity and resistance in vivo: advantages, limitations, and
appropriate usage. Am J Physiol Endocrinol Metab 2008, 294:E15-E26.
26. Caccamo G, Bonura F, Bonura F, Vitale G, Novo G, Evola S, Evola G,
Grisanti MR, Novo S: Insulin resistance and acute coronary syndrome.
Atherosclerosis 2010, 211:672-675.
27. Spencer M, Unal R, Zhu B, Rasouli N, McGehee RE Jr, Peterson CA, Kern PA:
Adipose Tissue Extracellular Matrix and Vascular Abnormalities in
Obesity and Insulin Resistance. J Clin Endocrinol Metab 2011.
28. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE,
Rood JC, Burk DH, Smith SR: Reduced adipose tissue oxygenation in
human obesity: evidence for rarefaction, macrophage chemotaxis, and
inflammation without an angiogenic response. Diabetes 2009, 58:718-725.
29. van de Woestijne AP, Monajemi H, Kalkhoven E, Visseren FL: Adipose tissue
dysfunction and hypertriglyceridemia: mechanisms and management.
Obes Rev 2011, 12:829-840.
30. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL,
Coviello AD, Florez JC, Fox CS, Levy D, Robins SJ, Arora P, Bhasin S, Lam CS,
Vasan RS, Melander O, Wang TJ: Cardiac natriuretic peptides, obesity, and
Verhagen et al. Cardiovascular Diabetology 2011, 10:100
http://www.cardiab.com/content/10/1/100
Page 8 of 9insulin resistance: evidence from two community-based studies. J Clin
Endocrinol Metab 2011, 96:3242-3249.
31. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M,
Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG,
Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L,
Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W,
Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive
investigators: Secondary prevention of macrovascular events in patients
with type 2 diabetes in the PROactive Study (PROspective pioglitAzone
Clinical Trial In macroVascular Events): a randomised controlled trial.
Lancet 2005, 366:1279-1289.
32. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM,
Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL,
Molitch ME, Nesto RW, Sako EY, Sobel BE: A randomized trial of therapies
for type 2 diabetes and coronary artery disease. N Engl J Med 2009,
360:2503-2515.
33. Shin JY, Lee HR, Lee DC: Increased arterial stiffness in healthy subjects
with high-normal glucose levels and in subjects with pre-diabetes.
Cardiovasc Diabetol 2011, 10:30.
34. Gomez-Marcos MA, Recio-Rodriguez JI, Patino-Alonso MC, gudo-Conde C,
Gomez-Sanchez L, Rodriguez-Sanchez E, Martin-Cantera C, Garcia-Ortiz L:
Relationship between intima-media thickness of the common carotid
artery and arterial stiffness in subjects with and without type 2 diabetes:
a case-series report. Cardiovasc Diabetol 2011, 10:3.
35. Wheatcroft SB, Williams IL, Shah AM, Kearney MT: Pathophysiological
implications of insulin resistance on vascular endothelial function. Diabet
Med 2003, 20:255-268.
36. Wassink AM, van der Graaf Y, Olijhoek JK, Visseren FL: Metabolic syndrome
and the risk of new vascular events and all-cause mortality in patients
with coronary artery disease, cerebrovascular disease, peripheral arterial
disease or abdominal aortic aneurysm. Eur Heart J 2008, 29:213-223.
37. Tenenbaum A, Fisman EZ: “The metabolic syndrome... is dead": these
reports are an exaggeration. Cardiovasc Diabetol 2011, 10:11.
38. Faber DR, de Groot PG, Visseren FL: Role of adipose tissue in haemostasis,
coagulation and fibrinolysis. Obes Rev 2009.
39. Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G: Insulin
directly reduces platelet sensitivity to aggregating agents. Studies in
vitro and in vivo. Diabetes 1988, 37:780-786.
40. Kim JA, Montagnani M, Koh KK, Quon MJ: Reciprocal relationships
between insulin resistance and endothelial dysfunction: molecular and
pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
41. Goff DC Jr, D’Agostino RB Jr, Haffner SM, Otvos JD: Insulin resistance and
adiposity influence lipoprotein size and subclass concentrations. Results
from the Insulin Resistance Atherosclerosis Study. Metabolism 2005,
54:264-270.
42. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for
quantifying insulin secretion and resistance. Am J Physiol 1979, 237:
E214-E223.
doi:10.1186/1475-2840-10-100
Cite this article as: Verhagen et al.: Insulin resistance increases the
occurrence of new cardiovascular events in patients with manifest
arterial disease without known diabetes. The SMART study.
Cardiovascular Diabetology 2011 10:100.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Verhagen et al. Cardiovascular Diabetology 2011, 10:100
http://www.cardiab.com/content/10/1/100
Page 9 of 9